<DOC>
	<DOCNO>NCT02105454</DOCNO>
	<brief_summary>In study , participant hepatitis C virus ( HCV ) genotype 1 ( GT1 ) fail prior direct-acting antiviral ( DAA ) therapy receive Grazoprevir ( MK-5172 ) + Elbasvir ( MK-8742 ) + Ribavirin ( RBV ) evaluate sustain virologic response ( SVR ) use drug combination .</brief_summary>
	<brief_title>Study Grazoprevir ( MK-5172 ) + Elbasvir ( MK-8742 ) + Ribavirin Participants With Chronic Hepatitis C Who Failed Prior Direct-Acting Antiviral Therapy ( MK-5172-048 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Inclusion criterion : Documented chronic HCV GT1 infection ( evidence nontypable mixed genotype ) Absence cirrhosis , cirrhosis criterion : METAVIR F4 , Fibroscan result &gt; 12.5 kPa , FibroSure® ( Fibrotest® ) score &gt; 0.75 + aspartate aminotransferase ( AST ) : platelet ratio index ( APRI ) &gt; 2 Prior regimen contain approve DAA ( boceprevir , telaprevir , simeprevir , sofosbuvir ) , pegylated interferon , and/or RBV Participants reproductive potential must agree remain truly abstinent use ( partner use ) 2 acceptable method birth control least 2 week prior Day 1 continue least 6 month last dose study drug , longer dictate local regulation Exclusion criterion : Received HCV regimen contain DAA exception boceprevir , telaprevir , simeprevir , sofosbuvir combination pegylated interferon and/or RBV Evidence decompensated liver disease cirrhosis Coinfected hepatitis B virus human immunodeficiency virus ( HIV ) History malignancy &lt; =5 year prior sign inform consent except adequately treat basal cell squamous cell skin cancer situ cervical cancer carcinoma situ ; evaluation active suspected malignancy Evidence hepatocellular carcinoma ( HCC ) evaluation HCC Currently participate participate study investigational compound within 30 day sign informed consent willing refrain participate another study course study Clinicallyrelevant drug alcohol abuse within 12 month screen Pregnant , breastfeeding , expect conceive donate egg sperm least 2 week prior Day 1 continue throughout treatment follow , longer dictate local regulation Male participant whose female partner ( ) is/are pregnant Organ transplant ( include hematopoietic stem cell transplant ) cornea hair Poor venous access History gastric surgery ( e.g. , staple , bypass ) history malabsorption disorder ( e.g. , celiac sprue disease ) Hemoglobinopathy , include , limited , thalassemia major Any medical condition requiring , likely require , chronic systemic administration corticosteroid course trial Evidence history chronic hepatitis cause HCV , include limited nonalcoholic steatohepatitis ( NASH ) , druginduced hepatitis , autoimmune hepatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>